Use the hyperlinks, where available to access additional clinical trial information.
An Open-Label, Multicenter, Phase I/IB Trial Evaluating the Safety and Pharmacokinetics of Escalating Doses of BTCT4465A as a Single Agent and Combined With Atezolizumab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia
This is trial includes a does escalation and expansion stage. In the dose escalation stage, patients will receive BTCT4465A (Mosunetuzumab) via intravenous (IV) infusion or subcutaneous (SC) injection as a single-agent or in combination with Atezolizumab. This stage will inform the recommended dose in the dose expansion stage of the study.